AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Baxter International: Morgan Stanley maintains a 'Underweight' Rating, The Target Price is $27
ByAinvest
Tuesday, Jul 15, 2025 10:00 am ET1min read
Morgan Stanley maintains 'Underweight' rating on Baxter International(BAX).
The target price is $27, compare with $28 previously.
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-07-15 | Morgan Stanley | Maintains | Underweight | Underweight | $27 | $28 |
| 2025-07-09 | Citigroup | Maintains | Neutral | Neutral | $32 | $34 |
| 2025-07-08 | Evercore ISI Group | Maintains | Outperform | Outperform | $42 | $44 |
[Recent Earning Results] Baxter International posted the Q1 of its 2025 financial results on 5/6/2025, reporting total revenue of USD 2625.00 million in the first quarter, up 5.42% from USD 2490.00 million year over year, reporting net income of USD 126.00 million in the first quarter, up 223.08% from USD 39.00 million year over year.
[Company Profile] Baxter International Inc. was incorporated under Delaware law in 1931. The company provides a broad portfolio of essential healthcare products, including sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet